Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 68.8%

Neg 68.8% Neu 0% Pos 0%

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $5.5 to $3.